IQVIA Holdings Inc. $IQV Stock Holdings Boosted by Cantillon Capital Management LLC

Cantillon Capital Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,941,144 shares of the medical research company’s stock after purchasing an additional 14,210 shares during the quarter. IQVIA comprises 2.4% of Cantillon Capital Management LLC’s holdings, making the stock its 17th biggest position. Cantillon Capital Management LLC’s holdings in IQVIA were worth $437,553,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth $27,000. Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA in the third quarter worth $30,000. Activest Wealth Management increased its holdings in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the period. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of IQVIA during the fourth quarter valued at about $35,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a report on Thursday, May 7th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Mizuho set a $215.00 target price on IQVIA in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Price Performance

NYSE:IQV opened at $183.56 on Monday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s 50-day moving average price is $172.12 and its 200 day moving average price is $194.79. IQVIA Holdings Inc. has a 52-week low of $147.62 and a 52-week high of $247.04. The firm has a market cap of $30.64 billion, a P/E ratio of 22.75, a PEG ratio of 1.57 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.